Twenty-two Years of Failure to Set Up Undisputed Assays to Detect Patients with the Antiphospholipid Syndrome

ABSTRACT

The antiphospholipid syndrome is defined by the persistent presence of antiphospholipid antibodies in plasma of patients with a history of thrombosis and/or pregnancy morbidity. From the definition in 1985 onwards, confusion has arisen concerning who has the syndrome and who has not. Although the clinical criteria are well defined, there is ongoing discussion regarding serologic criteria. Lack of standardization of the assays that define the serologic criteria, notably phospholipids-dependent coagulation assays, and enzyme-linked immunosorbent assays (ELISAs) for anticardiolipin and anti-β2 glycoprotein I, have led to heated arguments regarding which population(s) of antibodies should be measured to detect a patient at risk for (recurrent) thrombosis or pregnancy complications. Everybody agrees on the need to better standardize the assays, but different views are held on how this should be achieved, and commercial interests have hampered consensus on which assays should be applied, how they should be performed, and the cutoff values that discriminate between pathologic and nonpathologic results. New prospective cohort studies to reevaluate the clinical significance of the available assays are essential, but the lack of sufficient patient numbers visiting single hospital facilities frustrates progress. This review discusses shortcomings of the current serologic assays, provides strategies to solve these shortcomings, and discusses new developments/assays to improve the specificity of such assays for thrombosis and pregnancy complications.

Antiphospholipid syndrome; anticardiolipin antibodies; lupus anticoagulant; β2 glycoprotein I

REFERENCES

• 1 Hughes G R. The anticardiolipin syndrome.  Clin Exp Rheumatol. 1985;  3 285-286
• 2 Levine J S, Branch D W, Rauch J. The antiphospholipid syndrome.  N Engl J Med. 2002;  346 752-763
• 3 Rosendaal F R. Risk factors for venous thrombosis: prevalence, risk, and interaction.  Semin Hematol. 1997;  34 171-187
• 4 Reber G, Arvieux J, Comby E et al.. Multicenter evaluation of nine commercial kits for the quantitation of anticardiolipin antibodies. The Working Group on Methodologies in Haemostasis from the GEHT (Groupe d'Etudes sur l'Hémostase et la Thrombose).  Thromb Haemost. 1995;  73 444-452
• 5 Wong R, Favaloro E, Pollock W et al.. A multi-centre evaluation of the intra-assay and inter-assay variation of commercial and in-house anti-cardiolipin antibody assays.  Pathology. 2004;  36 182-192
• 6 Arnout J, Meijer P, Vermylen J. Lupus anticoagulant testing in Europe: an analysis of results from the first European Concerted Action on Thrombophilia (ECAT) survey using plasmas spiked with monoclonal antibodies against human beta2-glycoprotein I.  Thromb Haemost. 1999;  81 929-934
• 7 Brandt J T, Triplett D A, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardization Committee of the ISTH.  Thromb Haemost. 1995;  74 1185-1190
• 8 Wong R C, Gillis D, Adelstein S et al.. Consensus guidelines on anti-cardiolipin antibody testing and reporting.  Pathology. 2004;  36 63-68
• 9 Wilson W A, Gharavi A E, Koike T et al.. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop.  Arthritis Rheum. 1999;  42 1309-1311
• 10 Miyakis S, Lockshin M D, Atsumi T et al.. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS).  J Thromb Haemost. 2006;  4 295-306
• 11 McNeil H P, Simpson R J, Chesterman C N, Krilis S A. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H).  Proc Natl Acad Sci U S A. 1990;  87 4120-4124
• 12 Galli M, Comfurius P, Maassen C et al.. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor.  Lancet. 1990;  335 1544-1547
• 13 de Laat H B, Derksen R H, Urbanus R T, Roest M, de Groot P G. beta2-glycoprotein I-dependent lupus anticoagulant highly correlates with thrombosis in the antiphospholipid syndrome.  Blood. 2004;  104 3598-3602
• 14 Haupt H, Schwick H G, Storiko K. On a hereditary beta-2-glycoprotein I deficiency.  Humangenetik. 1968;  5 291-293
• 15 Sheng Y, Reddel S W, Herzog H et al.. Impaired thrombin generation in beta 2-glycoprotein I null mice.  J Biol Chem. 2001;  276 13817-13821
• 16 de Laat B, Derksen R HWM, van Lummel M, Pennings M T, de Groot P G. Pathogenic anti-β₂-glycoprotein I antibodies recognize domain I of β₂-glycoprotein I only after a conformational change.  Blood. 2005;  107 1916-1924
• 17 Kuwana M, Matsuura E, Kobayashi K et al.. Binding of {beta}2-glycoprotein I to anionic phospholipids facilitates processing and presentation of a cryptic epitope that activates pathogenic autoreactive T cells.  Blood. 2005;  105 1552-1557
• 18 Willems G M, Janssen M P, Pelsers M M et al.. Role of divalency in the high-affinity binding of anticardiolipin antibody-beta 2-glycoprotein I complexes to lipid membranes.  Biochemistry. 1996;  35 13833-13842
• 19 Harris E N, Gharavi A E, Boey M L et al.. Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus.  Lancet. 1983;  2 1211-1214
• 20 McNeil H P, Chesterman C N, Krilis S A. Anticardiolipin antibodies and lupus anticoagulants comprise separate antibody subgroups with different phospholipid binding characteristics.  Br J Haematol. 1989;  73 506-513
• 21 Hunt J E, McNeil H P, Morgan G J, Crameri R M, Krilis S A. A phospholipid-beta 2-glycoprotein I complex is an antigen for anticardiolipin antibodies occurring in autoimmune disease but not with infection.  Lupus. 1992;  1 75-81
• 22 Brandt J T, Triplett D A, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the Subcommittee on Lupus Anticoagulant / Antiphospholipid Antibody of the Scientific and Standardization Committee of the ISTH.  Thromb Haemost. 1995;  74 1185-1190
• 23 de Groot P G, Lutters B, Derksen R HWM, Lisman T, Meijers J CM, Rosendaal F R. Lupus anticoagulants and the risk of a first episode of deep venous thrombosis.  J Thromb Haemost. 2005;  3 1993-1997
• 24 Pengo V, Biasiolo A, Gresele P et al.. Participating Centres of Italian Federation of Thrombosis Centres (FCSA). Survey of lupus anticoagulant diagnosis by central evaluation of positive plasma samples.  J Thromb Haemost. 2007;  5 925-930
• 25 Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature.  Blood. 2003;  101 1827-1832
• 26 Pengo V, Biasiolo A, Bison E, Chantarangkul V, Tripodi A. Italian Federation of Anticoagulation Clinics (FCSA). Antiphospholipid antibody ELISAs: survey on the performance of clinical laboratories assessed by using lyophilized affinity-purified IgG with anticardiolipin and anti-beta2-Glycoprotein I activity.  Thromb Res. 2007;  120 127-133
• 27 Favaloro E J, Silverstrini R. Assessing the utility of anticardiolipin antibody assays: A cautious approach is suggested by high variation and limited consensus in multi-laboratory testing.  Am J Clin Pathol. 2002;  118 548-557
• 28 Audrain M A, Colonna F, Morio F, Hamidou M A, Muller J Y. Comparison of different kits in the detection of autoantibodies to cardiolipin and beta2glycoprotein 1.  Rheumatology (Oxford). 2004;  43 181-185
• 29 Kutteh W H, Franklin R D. Assessing the variation in antiphospholipid antibody (APA) assays: comparison of results from 10 centres.  Am J Obstet Gynecol. 2004;  191 440-448
• 30 Runchey S S, Folsom A R, Tsai M Y, Cushman M, McGovern P D. Anticardiolipin antibodies as a risk factor for venous thromboembolism in a population-based prospective study.  Br J Haematol. 2002;  119 1005-1010
• 31 Naess I A, Christiansen S C, Cannegieter S C, Rosendaal F R, Hammerstroem J. A prospective study of anticardiolipin antibodies as a risk factor for venous thrombosis in a general population (the HUNT study).  J Thromb Haemost. 2006;  4 44-49
• 32 Bizzaro N, Ghirardello A, Zampieri S et al.. Anti-prothrombin antibodies predict thrombosis in patients with systemic lupus erythematosus: a 15-year longitudinal study.  J Thromb Haemost. 2007;  5 1158-1164
• 33 Pengo V, Biasiolo A, Pegoraro C et al.. Antibody profiles for the diagnosis of antiphospholipid syndrome.  Thromb Haemost. 2005;  93 1147-1152
• 34 Galli M, Borrelli G, Jacobsen E M et al.. Clinical significance of different antiphospholipid antibodies in the WAPS (warfarin in the antiphospholipid syndrome) study.  Blood. 2007;  110 1178-1183
• 35 Ginsburg K S, Liang M H, Newcomer L et al.. Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis.  Ann Intern Med. 1992;  117 997-1002
• 36 Neville C, Rauch J, Kassis J et al.. Thromboembolic risk in patients with high titre anticardiolipin and multiple antiphospholipid antibodies.  Thromb Haemost. 2003;  90 108-115
• 37 Schulman S, Svenungsson E, Granqvist S. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Duration of Anticoagulation Study Group.  Am J Med. 1998;  104 332-338
• 38 Opatrny L, David M, Kahn S R, Shrier I, Rey E. Association between antiphospholipid antibodies and recurrent fetal loss in women without autoimmune disease: a metaanalysis.  J Rheumatol. 2006;  33 2214-2221
• 39 Favaloro E J, Wong R C, Jovanovich S, Robert-Thomson P. A review of beta-2-glycoprotein-I antibody testing results from a peer-driven multi-laboratory quality assurance program.  Am J Clin Pathol. 2007;  127 441-448
• 40 Ichikawa K, Tsutsumi A, Atsumi T et al.. A chimeric antibody with the human gamma1 constant region as a putative standard for assays to detect IgG beta2-glycoprotein I-dependent anticardiolipin and anti-beta2-glycoprotein I antibodies.  Arthritis Rheum. 1999;  42 2461-2470
• 41 Forastiero R, Martinuzzo M, Pombo G et al.. A prospective study of antibodies to beta2-glycoprotein I and prothrombin, and risk of thrombosis.  J Thromb Haemost. 2005;  3 1231-1238
• 42 Sailer T, Zoghlami C, Kurz C et al.. Anti-beta2-glycoprotein I antibodies are associated with pregnancy loss in women with the lupus anticoagulant.  Thromb Haemost. 2006;  95 796-801
• 43 Cucnik S, Kveder T, Krizaj I, Rozman B, Bozic B. High avidity anti-beta 2-glycoprotein I antibodies in patients with antiphospholipid syndrome.  Ann Rheum Dis. 2004;  63 1478-1482
• 44 De Laat B, Derksen R H, de Groot P G. High-avidity anti-beta glycoprotein I antibodies highly correlate with thrombosis in contrast to low-avidity anti-beta glycoprotein I antibodies.  J Thromb Haemost. 2006;  4 1619-1621
• 45 Bevers E M, Galli M, Barbui T, Comfurius P, Zwaal R F. Lupus anticoagulant IgG's (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin.  Thromb Haemost. 1991;  66 629-632
• 46 Oosting J D, Derksen R H, Bobbink I W et al.. Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C, or protein S: an explanation for their pathogenic mechanism?.  Blood. 1993;  81 2618-2625
• 47 Pengo V, Biasiolo A, Brocco T, Tonetto S, Ruffatti A. Autoantibodies to phospholipid-binding plasma proteins in patients with thrombosis and phospholipid-reactive antibodies.  Thromb Haemost. 1996;  75 721-724
• 48 Cugno M, Cabibbe M, Galli M et al.. Antibodies to tissue-type plasminogen activator (tPA) in patients with antiphospholipid syndrome: evidence of interaction between the antibodies and the catalytic domain of tPA in 2 patients.  Blood. 2004;  103 2121-2126
• 49 Bertolaccini M L, Mepani K, Sanna G, Hughes G R, Khamashta M A. Factor XII autoantibodies as a novel marker for thrombosis and adverse obstetric history in patients with systemic lupus erythematosus.  Ann Rheum Dis. 2007;  66 533-536
• 50 Bizzaro N, Ghirardello A, Zampieri S et al.. Anti-prothrombin antibodies predict thrombosis in patients with systemic lupus erythematosus: a 15-year longitudinal study.  J Thromb Haemost. 2007;  5 1158-1164
• 51 Rand J H, Wu X X, Andree H A et al.. Pregnancy loss in the antiphospholipid-antibody syndrome—a possible thrombogenic mechanism.  N Engl J Med. 1997;  337 154-160
• 52 Nakamura N, Kuragaki C, Shidara Y, Yamaji K, Wada Y. Antibody to annexin V has anti-phospholipid and lupus anticoagulant properties.  Am J Hematol. 1995;  49 347-348
• 53 de Laat B, Wu X X, van Lummel M, Derksen R H, de Groot P G, Rand J H. Correlation between antiphospholipid antibodies that recognize domain I of β2-glycoprotein I and a reduction in the anticoagulant activity of annexin A5.  Blood. 2007;  109 1490-1494
• 54 Pengo V, Biasiolo A, Pegoraro C et al.. Antibody profiles for the diagnosis of antiphospholipid syndrome.  Thromb Haemost. 2005;  93 1147-1152
• 55 Zoghlami-Rintelen C, Vormittag R, Sailer T et al.. The presence of IgG antibodies against beta2-glycoprotein I predicts the risk of thrombosis in patients with the lupus anticoagulant.  J Thromb Haemost. 2005;  3 1160-1165
• 56 Ruffatti A, Tonello M, Del R T et al.. Antibody profile and clinical course in primary antiphospholipid syndrome with pregnancy morbidity.  Thromb Haemost. 2006;  96 337-341
• 57 Simmelink M JA, Derksen R HWM, Arnout J, de Groot PhG. A simple method to discriminate between β₂-glycoprotein I– and prothrombin-dependent lupus anticoagulants.  J Thromb Haemost. 2003;  1 740-747
• 58 Pengo V, Biasiolo A, Pegoraro C, Iliceto S. A two-step coagulation test to identify antibeta-glycoprotein I lupus anticoagulants.  J Thromb Haemost. 2004;  2 702-707
• 59 Devreese K M. A functional coagulation test to identify anti-beta2-glycoprotein I dependent lupus anticoagulants.  Thromb Res. 2007;  119 753-759
• 60 De Laat B, Eckmann M, van Schagen M, Mertens K, van Mourik J A. Correlation between the potency of a beta2-glycoprotein I dependent lupus anticoagulant and the level of resistance to activated protein C [abstract P-S]. Presented at: XXIst Congress of the ISTH July 6–12, 2007 Geneva, Switzerland;
• 61 De Laat B, Derksen R H, Urbanus R T, de Groot P G. IgG antibodies that recognize epitope Gly40-Arg43 in domain I of {beta}2-glycoprotein I cause LAC and their presence correlates strongly with thrombosis.  Blood. 2005;  105 1540-1545
• 62 Petri M. Thrombosis and systemic lupus erythematosus: the Hopkins Lupus Cohort perspective.  Scand J Rheumatol. 1996;  25 191-193
• 63 Erkan D, Harrison M J, Levy R et al.. Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals.  Arthritis Rheum. 2007;  56 2382-2391
• 64 Kasahara H, Matsuura E, Kaihara K et al.. Antigenic structures recognized by anti-beta2-glycoprotein I auto-antibodies.  Int Immunol. 2005;  17 1533-1542
• 65 Eschwège V, Darnige L, Piette J C, Boffa M C. European Forum on Antiphospholipid Antibodies: report on the first meeting, 10–11 October 1997, Hôpital Saint-Louis, Paris.  Lupus. 1998;  7 439-444